Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
I am Intramural Blog

Old Drugs Find New Potential Against Hepatitis C

IRP Research Highlights a Novel Target to Stop Viral Infections

By Melissa Glim

Wednesday, July 28, 2021

drug-screening robot

Image credit: National Center for Advancing Translational Sciences

IRP researchers used specially designed robots to sift through more than 300,000 molecules for compounds that might be effective against the hepatitis C virus.

On July 28, health providers, researchers, patients, advocates, and governments across the globe observe World Hepatitis Day. Like this year’s theme, ‘Hepatitis Can’t Wait,’ IRP researchers are wasting no time utilizing the unique resources at the National Institutes of Health to identify innovative ways to combat the virus.

IRP Distinguished Investigator T. Jake Liang, M.D., for example, has focused his life’s work on understanding how hepatitis viruses infect, replicate, and persist in cells. The viruses he studies, hepatitis B and C, together affect more than 10 percent of the worlds’ population and are the most common causes of chronic liver disease and liver cancer. The two viruses were originally discovered in the 1980s by another IRP scientist, Harvey J. Alter, M.D., who shared the Nobel Prize in Medicine for that work in 2020. Nearly three decades later, Dr. Liang’s lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) worked with scientists at the National Center for Advancing Translational Sciences (NCATS) to develop a novel test to screen thousands of molecules using a technology called high-throughput screening, which led to the discovery of several compounds with the potential to block hepatitis C infection.

“I was inspired by a presentation I attended, more than ten years ago, on how Viagra came to the market,” Dr. Liang explains, noting that the medication was originally developed to treat high blood pressure before being repurposed for erectile dysfunction. “That’s when I thought of this project to repurpose existing drugs for hepatitis C.”

researchers working in the lab

More From the IRP
Blog
IRP’s Harvey Alter Awarded Nobel Prize

At the time, the only therapy for hepatitis C was a drug called interferon, which was only effective in about 20 percent of patients and came with harsh side effects. Pharmaceutical companies were focusing on various parts of the hepatitis C infection process and developing treatments to interfere with those steps, but Dr. Liang decided to take the opposite approach: find a compound that blocks viruses from infecting cells in petri dishes and then work backwards to understand how exactly it does that.

“It took a while, but fortunately, we were successful in developing a set of screening platforms for high-throughput screens of thousands of compounds very rapidly,” Dr. Liang says.

High-throughput screening uses robotics to combine and test vast sets of chemical compounds against a specific molecule or type of cell — in this case the hepatitis C virus — and search for interactions between them. The test Dr. Liang’s team and their NCATS collaborators developed led to the identification of several promising molecules, some of which had never been used for therapeutic purposes previously. Others belonged to a class of compounds previously approved for use as antihistamines, which reduce allergy symptoms like congestion and hives. The idea of repurposing those antihistamines for treating hepatitis C was attractive for several reasons.

cluster of hepatitis viruses

Image credit: U.S. Centers for Disease Control and Prevention

A cluster of hepatitis viruses, as seen through a transmission electron microscope.

“It takes a minimum of 10 years to get to a stage where a brand-new drug might show some kind of commercial benefit, and doing so can cost at least a billion dollars,” Dr. Liang says. On the other hand, by finding new uses for existing drugs, scientists can save that time and money while reducing the risks because they can proceed quicky to clinical trials as long as they stick to the approved dose.

There are drawbacks to this method, of course. Unless the pharmaceutical company is repurposing its own product, developers can run into patent issues. At the same time, the approved dose of a drug may not be high enough to alleviate the new condition.

That’s an issue Dr. Liang’s research team ran into with the antihistamine they selected for further study. Although laboratory studies showed a potent reaction between the drug and the hepatitis C virus, when tested at the approved dose in patients at the NIH Clinical Center, it didn’t block infection. The researchers solved this problem by modifying the molecule’s chemical structure with the addition of small groups of atoms, an alteration that made it more effective at blocking hepatitis C infection.

Meanwhile, Dr. Liang also needed to understand how the antihistamine was working to stop the virus.

“There are many steps you can interrupt in the infection process,” Dr. Liang says. “Most people target the machinery that allows the virus to replicate once it is inside the cell. We found this drug blocks the virus from getting into the cell before it has a chance to replicate.”

During the infection process, a virus attaches to the outside of a cell and then begins to fuse with the cell. This allows genetic material from the virus to enter the cell, where it hijacks the cell’s machinery and starts making copies of itself. The drug Dr. Liang’s lab focused on binds to the coating that surrounds the virus and prevents it from fusing with the cell.

Dr. T. Jake Liang

Since Dr. Liang published his findings in 2015 on the new and repurposed compounds his drug screen identified, an unrelated antiviral combination therapy was approved by the U.S. Food and Drug Administration in 2017. However, because the new therapy doesn’t work for everyone, he believes there may be room in the market for another treatment based on his discovery if a company wants to carry out clinical trials. In the meantime, his team’s discovery has important implications for both the value of repurposing drugs and the utility of a drug that interrupts fusion of a virus with a cell.

“These studies provided us with new, fundamental knowledge about viral infections specifically and biology in general,” says Dr. Liang. “When we studied the mechanism of the antihistamines and the other compounds that showed activity against hepatitis C, we found they were all targeting the same step of viral infection — that is, viral fusion.”

Having realized that the fusion process was common across all viruses, Dr. Liang’s team is now testing compounds that interrupt the process in other infections, including hepatitis B and COVID-19.

“We may be converging on an attractive concept of creating a broad-spectrum antiviral,” says Dr. Liang. “A certain compound may be active against many different classes of virus. These findings provided novel fundamental knowledge about the biology of viral infection that we may be able to leverage against other illnesses.”

Subscribe to our weekly newsletter to stay up-to-date on the latest breakthroughs in the NIH Intramural Research Program.


Category: IRP Discoveries
Tags: accomplishments, hepatitis C, hepatitis, liver, virus, virology, drug development, high-throughput screening, COVID-19

Related Blog Posts

  • Simple Blood Test May Thwart a Complicated Cancer
  • Leading the Charge Against Infectious Disease
  • Three-Minute Talks Showcase Smooth-Talking Scientists
  • IRP Pushes Forward in Fight Against Pandemic Virus
  • IRP Scientists Continue Efforts to Quell Pandemic

This page was last updated on Tuesday, May 23, 2023

Blog menu

  • Contributing Authors
    • Anindita Ray
    • Brandon Levy
    • Devon Valera
    • Melissa Glim
  • Categories
    • IRP Discoveries
    • Profiles
    • Events
    • NIH History
    • IRP Life

Blog links

  • Subscribe to RSS feed

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search